Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

[Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].

Fehér J, Deák G, Müzes G, Láng I, Niederland V, Nékám K, Kárteszi M.

Orv Hetil. 1989 Dec 17;130(51):2723-7. Review. Hungarian.

PMID:
2574842
2.

[Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].

Deák G, Müzes G, Láng I, Niederland V, Nékám K, Gonzalez-Cabello R, Gergely P, Fehér J.

Orv Hetil. 1990 Jun 17;131(24):1291-2, 1295-6. Review. Hungarian.

PMID:
2195425
3.

[Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)].

Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J.

Orv Hetil. 1990 Apr 22;131(16):863-6. Hungarian.

PMID:
2345633
4.

Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent.

Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G.

Diabetes Nutr Metab. 2002 Aug;15(4):222-31.

PMID:
12416659
5.
6.

Hepatoprotective and immunomodulatory effects of antioxidant therapy.

Láng I, Deák G, Nékám K, Müzes G, González-Cabello R, Gergely P, Fehér J.

Acta Med Hung. 1988;45(3-4):287-95.

PMID:
3074277
7.

[Controlled study of the effect of silymarin on alcoholic liver disease].

Bunout D, Hirsch S, Petermann M, de la Maza MP, Silva G, Kelly M, Ugarte G, Iturriaga H.

Rev Med Chil. 1992 Dec;120(12):1370-5. Spanish.

PMID:
1343377
8.

Hepatoprotective and immunological effects of antioxidant drugs.

Láng I, Nékám K, González-Cabello R, Mũzes G, Gergely P, Fehér J.

Tokai J Exp Clin Med. 1990 May;15(2-3):123-7.

PMID:
1983370
9.

[Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].

Pár A, Róth E, Rumi G Jr, Kovács Z, Nemes J, Mózsik G.

Orv Hetil. 2000 Jul 23;141(30):1655-9. Hungarian.

PMID:
10962902
10.

Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.

Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sánchez de la Cuesta F.

Int J Clin Pharmacol Ther. 2002 Jan;40(1):2-8.

PMID:
11841050
11.

Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers.

Láng I, Nékám K, Deák G, Müzes G, Gonzales-Cabello R, Gergely P, Csomós G, Fehér J.

Ital J Gastroenterol. 1990 Oct;22(5):283-7.

PMID:
1983711
12.

[Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients].

Trinchet JC, Coste T, Lévy VG, Vivet F, Duchatelle V, Legendre C, Gotheil C, Beaugrand M.

Gastroenterol Clin Biol. 1989;13(2):120-4. French.

PMID:
2707520
13.

Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.

Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B.

J Hepatol. 1989 Jul;9(1):105-13.

PMID:
2671116
14.
15.

Oxidative stress in the liver and biliary tract diseases.

Fehér J, Lengyel G, Blázovics A.

Scand J Gastroenterol Suppl. 1998;228:38-46. Review.

PMID:
9867111
16.

Short term treatment of type II hyperlipoproteinaemia with silymarin.

Somogyi A, Ecsedi GG, Blázovics A, Miskolczi K, Gergely P, Fehér J.

Acta Med Hung. 1989;46(4):289-95.

PMID:
2699920
17.

Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.

Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.

Fundam Clin Pharmacol. 2009 Jun;23(3):359-65. doi: 10.1111/j.1472-8206.2009.00681.x. Epub 2009 May 7.

PMID:
19453758
18.

[The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis (author's transl)].

Benda L, Dittrich H, Ferenzi P, Frank H, Wewalka F.

Wien Klin Wochenschr. 1980 Oct 10;92(19):678-83. German.

PMID:
7008367
19.

[Silymarin treatment of alcoholic liver disease].

[No authors listed]

Orv Hetil. 1990 Jul 22;131(29):1607-9. Hungarian. No abstract available.

PMID:
2392321
20.

Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.

Halmy L, Dávid K, Nagy I, Stotz G, Kelemen JT.

Acta Physiol Hung. 1984;64(3-4):461-70.

PMID:
6152370

Supplemental Content

Support Center